Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 6.1% - Here's Why

Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report)'s share price was up 6.1% during mid-day trading on Friday . The company traded as high as $19.05 and last traded at $18.88. Approximately 17,137 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 70,556 shares. The stock had previously closed at $17.79.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a research report on Thursday.

Pulse Biosciences Price Performance

The business's 50-day moving average price is $18.06 and its two-hundred day moving average price is $16.95.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period in the previous year, the company posted ($0.19) earnings per share.

Insider Buying and Selling

In other news, Director Robert W. Duggan acquired 56,054 shares of the stock in a transaction on Wednesday, December 11th. The stock was acquired at an average cost of $17.35 per share, for a total transaction of $972,536.90. Following the completion of the transaction, the director now directly owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. This trade represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of the firm's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the sale, the chief executive officer now directly owns 63,172 shares in the company, valued at approximately $1,100,456.24. This represents a 44.18 % decrease in their position. The disclosure for this sale can be found here. 71.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Quest Partners LLC bought a new stake in shares of Pulse Biosciences during the second quarter worth $91,000. Creative Planning boosted its holdings in shares of Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company's stock valued at $384,000 after acquiring an additional 11,667 shares in the last quarter. Franklin Resources Inc. bought a new stake in Pulse Biosciences during the 3rd quarter worth $378,000. Rhumbline Advisers increased its holdings in Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock worth $288,000 after purchasing an additional 1,608 shares in the last quarter. Finally, Barclays PLC raised its position in Pulse Biosciences by 361.4% in the third quarter. Barclays PLC now owns 30,306 shares of the company's stock valued at $530,000 after purchasing an additional 23,738 shares during the last quarter. Institutional investors own 76.95% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.